May 16, 2019. The dietary supplement industry has made substantial progress in
weeding out bad actors since the “wild, wild West”, largely unregulated days of the mid-
1990’s. We support FDA’s recent efforts to crack down on manufacturers who make false or
misleading claims about their dietary supplements.
On Medical Treatments & Products
NCHR Testimony on Mannitol Inhalation Powder for Cystic Fibrosis
May 9, 2018. It is uncertain if the benefits outweigh the risks based on the data discussed today. However, there should be sufficient evidence of both safety and efficacy before approval.
Read More »NCHR Report: The Health Risks of MRIs with Gadolinium-Based Contrast Agents
Gadolinium-based contrast agents can improve the diagnostic accuracy of MRIs, however gadolinium can stay in the body for months or years. There are many unanswered questions about who develops health problems related to gadolinium, how to determine if symptoms are due to gadolinium, and how to prevent or treat gadolinium-related conditions.
Read More »NCHR Public Comment to FDA on breast implant safety
April 26, 2019. NCHR submitted a comment to the FDA regarding the safety of breast implants, making suggestions for patient checklists, registry changes, and more.
Read More »NCHR Testimony on the safety and effectiveness of bacitracin for intramuscular injection for the treatment of infants with pneumonia
April 26, 2019. Not requiring scientific evidence to keep this product on the market would set a terrible precedent, and other companies would demand the same treatment. We urge the committee to prevent that precedent by voting to rescind approval of IM bacitracin until data are submitted establishing its benefits for another indication.
Read More »